Patents Assigned to Coley Pharmaceutical GmbH
-
Publication number: 20110206719Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: March 14, 2011Publication date: August 25, 2011Applicants: COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, INC.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Patent number: 7998492Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.Type: GrantFiled: October 29, 2003Date of Patent: August 16, 2011Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Publication number: 20110135605Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having semi-soft backbone.Type: ApplicationFiled: November 15, 2010Publication date: June 9, 2011Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Navneet K. Ahluwalia, Susan M. Efler, Heather L. Davis, Jörg Vollmer
-
Patent number: 7956043Abstract: The invention relates to a class of CpG immunostimulatory oligonucleotides containing a 5?TCG motif or a CG at or near the 5? end that are useful for stimulating an immune response.Type: GrantFiled: December 11, 2003Date of Patent: June 7, 2011Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Marion Jurk, Jorg Vollmer, Eugen Uhlmann
-
Publication number: 20110033421Abstract: Methods and compositions are provided for extending the clinical utility of IFN-? in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-? treatment and reduce IFN-? treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.Type: ApplicationFiled: July 13, 2010Publication date: February 10, 2011Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc., University of Iowa Research FoundationInventors: Gunther Hartmann, Robert L. Bratzler, Arthur M. Krieg
-
Publication number: 20100316659Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: December 9, 2009Publication date: December 16, 2010Applicants: COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, INC.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Publication number: 20100272785Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: ApplicationFiled: August 8, 2008Publication date: October 28, 2010Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer
-
Patent number: 7820379Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.Type: GrantFiled: March 18, 2005Date of Patent: October 26, 2010Assignee: Coley Pharmaceutical GmbHInventors: Stefan Bauer, Grayson B. Lipford, Hermann Wagner
-
Patent number: 7795235Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: December 17, 2008Date of Patent: September 14, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7776344Abstract: Methods and compositions are provided for extending the clinical utility of IFN-? in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-? treatment and reduce IFN-? treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.Type: GrantFiled: July 8, 2005Date of Patent: August 17, 2010Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Gunther Hartmann, Robert L. Bratzler, Arthur M. Krieg
-
Publication number: 20100189772Abstract: The invention relates to methods and products for the treatment of viral infection using a combination of anti-viral agents and TLR ligands. The invention also relates to screening assays, associated products, kits, and in vitro methods.Type: ApplicationFiled: September 27, 2007Publication date: July 29, 2010Applicants: COLEY PHARMACEUTICAL GROUP, INC, COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, LTDInventors: Jorg Vollmer, Marion Jurk, Eugen Uhlmann, Harald Debelak, Robert L. Bratzler, Alain Vicari
-
Publication number: 20100183639Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: ApplicationFiled: November 10, 2009Publication date: July 22, 2010Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Publication number: 20100144846Abstract: The invention relates to immunostimulatory RNA oligonucleotides (ORN). In particular the ORN have an immunostimulatory ORN motif directly or indirectly flanked by a 3? poly G motif and optionally a 5? poly-G motif. The invention also relates to methods including therapeutic methods and screening methods and related kits for use of the ORN.Type: ApplicationFiled: October 26, 2007Publication date: June 10, 2010Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer, Eugen Uhlmann
-
Patent number: 7662949Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: GrantFiled: November 22, 2006Date of Patent: February 16, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Publication number: 20090306177Abstract: Double-stranded short interfering ribonucleic acid (siRNA) are modified to reduce or eliminate their immunostimulatory effect without significantly affecting their gene silencing effect. Modified siRNA include one or more 2? sugar modifications and, optionally, internucleotide linkages on the sense strand. Compositions containing the modified siRNA and methods of making and using the modified siRNA are disclosed. New and previously characterized siRNA can be synthesized to incorporate modifications according to the invention.Type: ApplicationFiled: September 15, 2006Publication date: December 10, 2009Applicants: Coley Pharmaceutical GmbH, Qiagen GmbHInventors: Eugen Uhlmann, Marion Jurk, Joerg Vollmer, Christian Schetter, Martin Weber, Ioanna Andreou, Stefan Pitsch
-
Patent number: 7615539Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: GrantFiled: September 27, 2004Date of Patent: November 10, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Publication number: 20090214578Abstract: Immunostimulatory single-stranded oligoribonucleotides (ssORN) with phosphodiester backbones induce TLR7-independent and MyD88-dependent immune activation. These immunostimulatory ssORN are useful to induce a ThI-like immune response in a subject, to induce an antigen-specific immune response in a subject, and to treat a subject having a cancer, an infectious disease, an allergic condition, or asthma.Type: ApplicationFiled: September 15, 2006Publication date: August 27, 2009Applicant: Coley Pharmaceutical GmbHInventor: Stefan Bauer
-
Publication number: 20090191188Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.Type: ApplicationFiled: February 26, 2009Publication date: July 30, 2009Applicants: University of Iowa Research Foundation, Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Christian Schetter, Jorg Vollmer
-
Patent number: 7566703Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20090137519Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: December 17, 2008Publication date: May 28, 2009Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann